Every 8-K that Silence Therapeutics Plc (SLN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SLN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLN filings page.
Silence Therapeutics plc entered into an underwriting agreement on August 11, 2026 to conduct an underwritten public offering of 12,962,963 American Depositary Shares (ADSs), each representing three ordinary shares. The ADSs are priced at $13.50 per ADS to the public, with underwriters purchasing at $12.69 per ADS, under an effective Form S-3 shelf registration and related S-3MEF filing.
The company granted underwriters a 30‑day option to buy up to an additional 1,944,444 ADSs. Gross proceeds are expected to be approximately $175 million, with estimated net proceeds of about $164.0 million, or $188.7 million if the option is fully exercised, in each case after underwriting discounts and estimated expenses. The offering is expected to close on or about August 13, 2026, subject to customary conditions. Jefferies, Morgan Stanley, Cantor and William Blair are acting as joint book‑running managers.
Silence Therapeutics plc reported positive topline results from the Phase 2 SANRECO trial of its siRNA candidate divesiran in 48 phlebotomy-dependent patients with polycythemia vera (PV). The 36-week, randomized, double-blind, placebo-controlled study evaluated divesiran 6 mg/kg given subcutaneously every six or twelve weeks.
The primary endpoint was met, with an 88% response rate in divesiran-treated patients versus 19% on placebo during weeks 18–36 (p<0.0001), defined as maintaining hematocrit below 45% without phlebotomies. In a sensitivity analysis (n=40), response was 89% vs 8% (p<0.0001). The mean number of phlebotomies from weeks 0–36 was 0.2 in the divesiran arm versus 2.1 with placebo (p<0.0001). Divesiran was generally well tolerated, with safety consistent with earlier studies and only two investigator-reported grade 1 anemia events.
All patients have completed the placebo-controlled portion and entered a three-year extension. Based on these results, Silence expects to initiate a Phase 3 trial in the first half of 2027, focused on Q12W dosing versus placebo.
Silence Therapeutics plc reported second quarter 2026 results showing continued operating losses but significantly reduced spending. For the three months ended June 30, 2026, revenue was $0 compared with $224 thousand a year earlier. The company recorded an operating loss of $13.9 million, improved from $24.0 million in the prior-year quarter, driven by lower research and development costs of $9.1 million versus $17.6 million and general and administrative expenses of $4.7 million versus $5.1 million. Net loss for the quarter was $12.3 million, compared with $27.4 million, with loss per share narrowing to $0.09 from $0.19.
For the six months ended June 30, 2026, revenue was $422 thousand versus $366 thousand and net loss was $27.2 million compared with $55.9 million, or $0.19 per share versus $0.39. On the balance sheet at June 30, 2026, cash and cash equivalents were $72.1 million and total assets were $106.4 million, with total liabilities of $67.9 million. The company continues to advance its siRNA pipeline, including divesiran for polycythemia vera and SLN312 (AZD1705) for dyslipidemia.
Silence Therapeutics plc entered into a separation and release agreement with former executive Craig Tooman dated July 10, 2026, following his December 14, 2025 Separation Date. The company will provide $655,000 in 12 months of salary continuation, a $250,000 lump-sum severance payment, and reimbursements including $40,000 of legal fees, a $283,746.03 2025 bonus, $46,896.48 of healthcare premiums, and up to $20,000 of tax-provider fees.
Mr. Tooman’s equity awards will continue vesting for 45 days after the Separation Date, with extended post-termination option exercise periods of up to 24 months for options under the 2023 Equity Incentive Plan and 12 months for options under the 2018 Long Term Incentive Plan. Any unvested options may vest upon a change of control within 12 months after the Separation Date, conditioned on his continued compliance with the Separation Agreement, which also includes confidentiality, non-disparagement and non-solicitation covenants and a release of claims.
Silence Therapeutics furnished an updated corporate presentation outlining progress across its RNA interference (siRNA) pipeline for rare blood and cardiometabolic diseases. The 8-K is a Regulation FD disclosure and the materials are furnished, not filed, under securities laws.
The presentation highlights divesiran for polycythemia vera, where a 21‑patient Phase 1 study showed marked reductions in phlebotomy dependence with a favorable safety profile. A 48‑patient, placebo‑controlled Phase 2 trial is fully enrolled, with topline results expected in 3Q 2026.
SLN312, an ANGPTL3‑targeting siRNA for dyslipidemia, showed robust lipid and ANGPTL3 reductions in Phase 1; Silence expects to regain global rights after Phase 1. Preclinical programs include SLN365 (GPR146) for familial hypercholesterolemia, targeting an IND in 2H 2027, and SLN098 (INHBE) for obesity and metabolic disease, with ~90% target knockdown in primates and a potential IND by 2027 year‑end.
Silence Therapeutics plc reports that shareholders approved nine resolutions at its 2026 Annual General Meeting held on June 16, 2026. Investors re‑appointed directors Rhonda Hellums and James Ede‑Golightly, with 47,160,731 and 52,112,045 votes cast in favor, respectively.
Shareholders gave advisory approval to executive compensation and the directors’ remuneration report, and adopted the 2025 U.K. statutory annual accounts and reports. They also ratified and re‑appointed PricewaterhouseCoopers LLP as both U.S. independent registered public accounting firm and U.K. statutory auditors, and authorized the Audit & Risk Committee to set the auditors’ remuneration. Application of Article 159 of the Company’s articles of association was also approved.
Silence Therapeutics plc reported new follow-up results from its Phase 1 SANRECO study of divesiran, an siRNA therapy for polycythemia vera, showing durable reductions in phlebotomy needs and potential quality-of-life benefits.
Among 21 phlebotomy-dependent patients, 80 phlebotomies were required in the six months before treatment versus only 5 during the active dosing period, all in patients with uncontrolled hematocrit above 45%. In the 16-week follow-up after the final dose, only 4 phlebotomies were reported, and for 14 patients with extended follow-up the median time to first phlebotomy was 287 days. Most patients saw improvements in MPN-10 symptom scores, and divesiran was generally well tolerated with mainly mild, transient injection-site reactions and no dose-limiting toxicities.
The ongoing randomized, placebo-controlled Phase 2 SANRECO study in 48 patients is testing 6 mg divesiran given every 6 or 12 weeks, with topline results expected in August 2026.
Silence Therapeutics plc entered into a new Open Market Sale Agreement with Jefferies LLC, establishing an at-the-market program for American Depositary Shares under its Form S-3 shelf registration statement. This replaces and terminates the company’s prior Open Market Sale Agreement with Jefferies.
The company also updated its tax risk disclosures to state that, after further analysis, it currently believes it was not classified as a passive foreign investment company for the taxable year ended December 31, 2025, while emphasizing that its PFIC status remains a complex, annual, facts-based determination.
Silence Therapeutics plc reported first quarter 2026 results, showing higher collaboration revenue and a much narrower loss as it advances its siRNA pipeline. Collaboration revenue from AstraZeneca rose to $0.4 million from $0.1 million a year earlier.
Research and development expenses fell to $9.1 million from $20.8 million, largely after completing zerlasiran Phase 3 readiness in 2025. Net loss improved to $15.0 million, or $0.11 per share, compared with a $28.5 million loss, or $0.20 per share, in the prior-year quarter. The company held $70.1 million in cash, cash equivalents and short-term investments as of March 31, 2026, and its Phase 2 SANRECO trial of divesiran in polycythemia vera remains on track for topline results in August 2026.
Silence Therapeutics reported a larger full-year 2025 net loss while highlighting progress across its siRNA pipeline. Collaboration revenue dropped to $0.6M from $43.3M, driving a wider net loss of $88.6M, or $0.63 per share, versus a $45.3M loss in 2024.
Cash, cash equivalents and short-term investments totaled $85.1M as of December 31, 2025. The company emphasized divesiran for polycythemia vera, with the Phase 2 SANRECO trial fully enrolled and topline results expected in 3Q 2026, and completed core Phase 3 readiness work for zerlasiran in high Lp(a).
AstraZeneca completed a Phase 1 interim analysis of SLN312 in dyslipidemia and then decided not to pursue development beyond Phase 1, after which Silence will regain exclusive global rights. Silence also advanced new preclinical programs SLN365 and SLN098 and noted leadership changes with Iain Ross serving as Interim Principal Executive Officer.
Silence Therapeutics plc is undergoing significant leadership changes, as President, Chief Executive Officer and director Craig Tooman agreed by mutual consent to end his employment and step down from the Board effective December 14, 2025.
On the same date, Board Chairman Iain Ross was appointed as interim principal executive officer, with additional compensation terms still to be determined and to be covered in a later amendment. The Board also appointed James Ede-Golightly, age 46, to serve as a director with an initial term running until the Company’s 2026 annual general meeting, with his director compensation to be finalised later. The Company issued a December 15, 2025 press release about these changes, filed as Exhibit 99.1.
Silence Therapeutics plc furnished an 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025, along with recent business highlights. The press release is provided as Exhibit 99.1 and is incorporated by reference. The information under Item 2.02 is furnished and not deemed filed under the Exchange Act.
The company’s American Depositary Shares trade on Nasdaq under SLN, with each ADS representing 3 ordinary shares of nominal value £0.05 per share.
Silence Therapeutics plc reported a clinical milestone under Other Events: it has completed enrollment in the SANRECO Phase 2 study of divesiran for treating polycythemia vera (PV).
The company furnished a press release as Exhibit 99.1. The information, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.
Silence Therapeutics plc reported that Michael Davidson resigned from its board of directors on August 11, 2025, stepping down immediately from the Board and from the Audit and Risk, Remuneration, and Science & Technology Committees. The company states that he left to focus on other time commitments, including his role as Chief Executive Officer of NewAmsterdam Pharma Company N.V., and that his resignation was not due to any disagreement with the company, its management, or the Board.
After his departure, the Board reduced its size from five to four directors. The Board also appointed its chairman, Iain Ross, to the Audit and Risk Committee to fill the vacancy created by Dr. Davidson’s resignation, maintaining coverage of this key governance function.
Silence Therapeutics (NASDAQ:SLN) filed a routine Form 8-K disclosing voting results from its 26 June 2025 Annual General Meeting. Shareholders approved all 13 resolutions, including the re-appointment of directors David Lemus, Tim McInerney, Iain Ross and Craig Tooman; an annual non-binding say-on-pay vote; ratification of PricewaterhouseCoopers LLP as both U.S. and U.K. auditors; adoption of the 2024 U.K. statutory accounts; and replacement of the company’s articles of association. Support levels exceeded 90% for most items (e.g., Craig Tooman re-elected with 78.23 M votes for vs. 28.4 k against). The board will continue to seek shareholder input on executive compensation annually. No other material business, strategic changes or financial disclosures were announced.